{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:48:24Z","timestamp":1793231304827,"version":"4.5.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jaip.2023.12.025","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T17:21:27Z","timestamp":1703265687000},"page":"911-918","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema"],"prefix":"10.1016","volume":"12","author":[{"given":"Marc A.","family":"Riedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bordone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Revenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny M.","family":"Cohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2023.12.025_bib1","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.12.025_bib2","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1808012","article-title":"Hereditary angioedema","volume":"382","author":"Busse","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.12.025_bib3","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13223-021-00537-2","article-title":"Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report","volume":"17","author":"Bork","year":"2021","journal-title":"Allergy Asthma Clin Immunol"},{"key":"10.1016\/j.jaip.2023.12.025_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.12968\/hmed.2019.80.7.391","article-title":"Hereditary angioedema: an update on causes, manifestations and treatment","volume":"80","author":"Longhurst","year":"2019","journal-title":"Br J Hosp Med (Lond)"},{"key":"10.1016\/j.jaip.2023.12.025_bib5","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/all.13582","article-title":"Gene therapy for C1 esterase inhibitor deficiency in a murine model of hereditary angioedema","volume":"74","author":"Qiu","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.12.025_bib6","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJMoa2109329","article-title":"Inhibition of prekallikrein for hereditary angioedema","volume":"386","author":"Fijen","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.12.025_bib7","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12016-021-08832-x","article-title":"Current and prospective targets of pharmacologic treatment of hereditary angioedema types 1 and 2","volume":"61","author":"Fijen","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2023.12.025_bib8","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMcp0803977","article-title":"Clinical practice. Hereditary angioedema","volume":"359","author":"Zuraw","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.12.025_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s13023-020-01570-x","article-title":"Clinical features of genetically characterized types of hereditary angioedema with normal C1 inhibitor: a systematic review of qualitative evidence","volume":"15","author":"Bork","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2023.12.025_bib10","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/all.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2023.12.025_bib11","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.anai.2017.01.015","article-title":"Anabolic androgen use in the management of hereditary angioedema: not so cheap after all","volume":"118","author":"Tse","year":"2017","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2023.12.025_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1186\/s13023-022-02536-x","article-title":"Long-term prophylaxis with androgens in the management of hereditary angioedema (HAE) in emerging countries","volume":"17","author":"Guo","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jaip.2023.12.025_bib13","series-title":"Cinryze [package insert]","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib14","series-title":"Cinryze [summary of product characteristics]","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib15","series-title":"Haegarda [package insert]","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib16","series-title":"Takhzyro [package insert]","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib17","series-title":"Orladeyo [package insert]","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.12.025_bib19","series-title":"Oral FXIIa inhibitor KV998086 suppresses FXII zymogen mediated kallikrein kinin system activation","author":"Murugesan","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib21","doi-asserted-by":"crossref","first-page":"13629","DOI":"10.1021\/acs.jmedchem.2c00921","article-title":"Sebetralstat (KVD900): a potent and selective small molecule plasma kallikrein inhibitor featuring a novel P1 group as a potential oral on-demand treatment for hereditary angioedema","volume":"65","author":"Davie","year":"2022","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.jaip.2023.12.025_bib22","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0140-6736(22)02406-0","article-title":"An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial","volume":"401","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2023.12.025_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12288","article-title":"Evaluation of patient-reported outcome measures for on-demand treatment of hereditary angioedema attacks and design of KONFIDENT, a phase 3 trial of sebetralstat","volume":"13","author":"Cohn","year":"2023","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jaip.2023.12.025_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108523","article-title":"In\u00a0vitro pharmacological profile of PHA-022121, a small molecule bradykinin B(2) receptor antagonist in clinical development","volume":"105","author":"Lesage","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.jaip.2023.12.025_bib25","doi-asserted-by":"crossref","first-page":"AB134","DOI":"10.1016\/j.jaci.2022.12.419","article-title":"Efficacy and safety of bradykinin B2 receptor inhibition with oral PHVS416 in treating hereditary angioedema attacks: results of RAPIDe-1 phase 2 trial","volume":"151","author":"Maurer","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.12.025_bib27","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/ene.15280","article-title":"Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis","volume":"29","author":"Mariottini","year":"2022","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jaip.2023.12.025_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1261\/rna.068916.118","article-title":"An investigational RNAi therapeutic targeting Factor XII (ALN-F12) for the treatment of hereditary angioedema","volume":"25","author":"Liu","year":"2019","journal-title":"RNA"},{"key":"10.1016\/j.jaip.2023.12.025_bib29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.3389\/fimmu.2016.00547","article-title":"Hereditary angioedema as a metabolic liver disorder: novel therapeutic options and prospects for cure","volume":"7","author":"Ameratunga","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.12.025_bib30","doi-asserted-by":"crossref","first-page":"8610","DOI":"10.1016\/S0021-9258(17)39516-9","article-title":"Structural organization of the human kininogen gene and a model for its evolution","volume":"260","author":"Kitamura","year":"1985","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jaip.2023.12.025_bib31","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/j.jaci.2008.12.063","article-title":"Acquired C1-inhibitor deficiency - report of 18 cases","volume":"123","author":"Ayg\u00f6ren-P\u00fcrs\u00fcn","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2023.12.025_bib32","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.jaip.2019.10.029","article-title":"A\u00a0case of acquired hereditary angioedema","volume":"8","author":"Sohn","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2023.12.025_bib33","doi-asserted-by":"crossref","DOI":"10.1097\/PG9.0000000000000091","article-title":"Hereditary angioedema post-liver transplant","volume":"2","author":"Al Rawahi","year":"2021","journal-title":"JPGN Rep"},{"key":"10.1016\/j.jaip.2023.12.025_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1089\/nat.2018.0754","article-title":"IONIS-PKK(Rx) a novel antisense inhibitor of prekallikrein and bradykinin production","volume":"29","author":"Ferrone","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jaip.2023.12.025_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/wrna.1594","article-title":"The powerful world of antisense oligonucleotides: from bench to bedside","volume":"11","author":"Quemener","year":"2020","journal-title":"Wiley Interdiscip Rev RNA"},{"key":"10.1016\/j.jaip.2023.12.025_bib36","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3390\/biomedicines9040433","article-title":"The challenges and strategies of antisense oligonucleotide drug delivery","volume":"9","author":"Gagliardi","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.jaip.2023.12.025_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aian.AIAN_298_17","article-title":"Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases","volume":"21","author":"Verma","year":"2018","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1016\/j.jaip.2023.12.025_bib38","doi-asserted-by":"crossref","first-page":"12388","DOI":"10.1093\/nar\/gkx960","article-title":"Asialoglycoprotein receptor 1 mediates productive uptake of N-acetylgalactosamine-conjugated and unconjugated phosphorothioate antisense oligonucleotides into liver hepatocytes","volume":"45","author":"Tanowitz","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jaip.2023.12.025_bib39","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.omtn.2019.02.024","article-title":"Delivery of GalNAc-conjugated splice-switching ASOs to non-hepatic cells through ectopic expression of asialoglycoprotein receptor","volume":"16","author":"Scharner","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jaip.2023.12.025_bib40","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/17425255.2019.1621838","article-title":"Pharmacokinetics and clinical pharmacology considerations of GalNAc(3)-conjugated antisense oligonucleotides","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jaip.2023.12.025_bib41","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ymthe.2020.06.015","article-title":"Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug","volume":"28","author":"Debacker","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaip.2023.12.025_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated assessment of the clinical performance of GalNAc(3)-conjugated 2\u2032-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.jaip.2023.12.025_bib43","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1056\/NEJMe2201729","article-title":"An antisense oligonucleotide for hereditary angioedema","volume":"386","author":"Longhurst","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.12.025_bib44","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJMoa1915035","article-title":"Antisense inhibition of prekallikrein to control hereditary angioedema","volume":"383","author":"Cohn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.12.025_bib45","series-title":"Phase 2 open-label extension study with donidalorsen treatment in patients with hereditary angioedema. Presented at the annual scientific meeting of the American College of Allergy","author":"Bordone","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib46","series-title":"In\u00a0vivo CRISPR\/Cas9 editing of KLKB1 in patients with HAE","author":"Longhurst","year":"2022"},{"key":"10.1016\/j.jaip.2023.12.025_bib47","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1055\/a-1926-2367","article-title":"The influence of plasma prekallikrein oligonucleotide antisense therapy on coagulation and fibrinolysis assays: a post-hoc analysis","volume":"122","author":"Fijen","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jaip.2023.12.025_bib48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/jns.12519","article-title":"Liver-directed drugs for transthyretin-mediated amyloidosis","volume":"27","author":"Brannagan","year":"2022","journal-title":"J\u00a0Peripher Nerv Syst"},{"key":"10.1016\/j.jaip.2023.12.025_bib49","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jaip.2023.12.025_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jaip.2023.12.025_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113324","article-title":"Gene therapy clinical trials, where do we go? An overview","volume":"153","author":"Arabi","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jaip.2023.12.025_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2023.12.025_bib53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.jaip.2023.12.025_bib54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","article-title":"Valoctocogene roxaparvovec gene therapy for hemophilia A","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2023.12.025_bib55","article-title":"Gene therapy advances: a meta-analysis of AAV usage in clinical settings","volume":"8","author":"Au","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaip.2023.12.025_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaip.2023.12.025_bib57","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","article-title":"CRISPR-Cas12a: functional overview and applications","volume":"43","author":"Paul","year":"2020","journal-title":"Biomed J"},{"key":"10.1016\/j.jaip.2023.12.025_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119711","article-title":"Ex\u00a0vivo cell-based CRISPR\/Cas9 genome editing for therapeutic applications","volume":"234","author":"Li","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jaip.2023.12.025_bib59","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv"},{"key":"10.1016\/j.jaip.2023.12.025_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2022.100664","article-title":"Using an extended treatment regimen of lanadelumab in the prophylaxis of hereditary angioedema: a single-centre experience","volume":"15","author":"Abuzakouk","year":"2022","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaip.2023.12.025_bib63","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1124\/jpet.123.001740","article-title":"STAR-0215 is a novel, long-acting monoclonal antibody inhibitor of plasma kallikrein for the potential treatment of hereditary angioedema","volume":"387","author":"Bedian","year":"2023","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jaip.2023.12.025_bib64","doi-asserted-by":"crossref","first-page":"AB136","DOI":"10.1016\/j.jaci.2022.12.426","article-title":"Initial results from a phase 1 single ascending dose clinical trial of STAR-0215, an investigational long-acting monoclonal antibody plasma kallikrein inhibitor for hereditary angioedema (HAE), in healthy subjects followed for at least 3 months","volume":"151","author":"Morabito","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823013880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219823013880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T01:28:47Z","timestamp":1729128527000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219823013880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2213219823013880"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2023.12.025","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2023.12.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}